I reckon this is one of the best small-cap growth shares to buy now

With its alluring prospects and modest-looking valuation, I’m tempted to buy this small-cap growth share operating in an attractive sector.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I think Adept Technologies (LSE: ADT) is one of the best small-cap growth shares for me to buy now.

The company describes itself as one of the UK’s “leading” independent providers of managed services for IT, connectivity, unified communications solutions, and cloud services. And the directors have been pursuing a growth agenda based on both organic progress and acquisitions.

Why I’m considering this small-cap growth share

Today’s full-year results report shows what the directors describe as “a resilient financial performance under highly challenging trading conditions.” And the company claims to have made “considerable progress” in its strategic ambitions, despite the disruption caused by the pandemic.

In the 12 months to 31 March, revenue declined by just over 6%. And adjusted diluted earnings per share slipped 20%. But cash flow held essentially flat. And the firm’s cash balance increased by almost 12% to just over £13m.

On top of that encouraging cash performance, net debt declined from almost £28m the prior year to just under £26m. When it came to dealing with real pound notes, Adept Technology did well during the year.

Just over 55% of overall revenue came from the public and healthcare sectors. And that figure grew from just under 45% the prior year. Those sectors tend to generate stable demand. So I see the firm’s advance as attractive. Meanwhile, revenue from cloud-based services increased by 9% to just over £25m, making it around 43% of total revenue.

I reckon Adept Technology is doing a good job migrating to business areas that are relevant now. Revenue from traditional telephony, for example, came in at just 19% of the total, down from 21% the year before. The situation makes me think of an old business aphorism: adapt or die.

A positive outlook

During the year, the company arranged an enlarged banking facility worth £50m “to support investment in growth.” And in April, the long-running acquisition programme continued with the purchase of a company called Datrix. The directors describe the new business as being focused on enterprise networks and security. And that, they reckon, enhances Adept Technology’s core capabilities and “strengthens its presence in the NHS vertical market.” 

Looking ahead, “strong” operational momentum from the fourth quarter has continued into the new trading year. And chief executive Phil Race is “confident” the opportunities for the business are robust. He reckons the technology market is “vibrant” and demand for ICT services is at an “all-time high and likely to remain so.”

Meanwhile, with the share price weak today, it’s sitting near-288p, as I write. And at that level, the forward-looking earnings multiple for the trading year to March 2022 is around 10. I reckon the valuation’s fair.

However, there are risks for shareholders. One is the potential for the company to ramp up debt if it becomes carried away with its acquisition programme. Another is the increasing reliance on the public and health sectors. If the company falls out of favour with a big public-sector customer, revenues, earnings and the share price could all crash together.

Nevertheless, I’m tempted to add the small-cap growth share to my long-term diversified portfolio for its potential to expand. I’d aim to hold for at least five years as the story unfolds.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

If I’d put £5,000 in Nvidia stock at the start of 2024, here’s what I’d have now

Nvidia stock was a massive winner in 2023 as the AI chipmaker’s profits surged across the year. How has it…

Read more »

Light bulb with growing tree.
Investing Articles

3 top investment trusts that ‘green’ up my Stocks and Shares ISA

I’ll be buying more of these investment trusts for my Stocks and Shares ISA given the sustainable and stable returns…

Read more »

Investing Articles

8.6% or 7.2%? Does the Legal & General or Aviva dividend look better?

The Aviva dividend tempts our writer. But so does the payout from Legal & General. Here he explains why he'd…

Read more »

a couple embrace in front of their new home
Investing Articles

Are Persimmon shares a bargain hiding in plain sight?

Persimmon shares have struggled in 2024, so far. But today's trading update suggests sentiment in the housing market's already improving.

Read more »

Market Movers

Here’s why the Unilever share price is soaring after Q1 earnings

Stephen Wright isn’t surprised to see the Unilever share price rising as the company’s Q1 results show it’s executing on…

Read more »

Investing Articles

Barclays’ share price jumps 5% on Q1 news. Will it soon be too late to buy?

The Barclays share price has been having a great time this year, as a solid Q1 gives it another boost.…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

The AstraZeneca share price lifts 5% on a top-and-bottom earnings beat

The AstraZeneca share price reached £120 today and helped push the FTSE 100 higher. Would I still buy this flying…

Read more »

Young black woman using a mobile phone in a transport facility
Market Movers

Meta stock slumps 13% after poor results. Here’s what I’ll do

Jon Smith flags up the reasons behind the fall in the Meta stock price overnight, along with his take on…

Read more »